At a median follow-up of 18 months, the 2-year probability of disease-free survival was 91.1% The same group reported results from a cohort of 80 patients with acute leukemias (71) transplanted with TCRαβ+/CD19+ depleted haplo grafts. This evidence concerns the gene CD19 and acute leukemia.